Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

@article{Giantonio2007BevacizumabIC,
  title={Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.},
  author={Bruce J. Giantonio and Paul J. Catalano and Neal J. Meropol and Peter J. O'dwyer and Edith Peterson Mitchell and Steven Robert Alberts and Michael Alan Schwartz and Al Bowen Benson},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 12},
  pages={1539-44}
}
PURPOSE Colorectal cancer is the second leading cause of cancer mortality in the United States. Antiangiogenic therapy with bevacizumab combined with chemotherapy improves survival in previously untreated metastatic colorectal cancer. This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer. PATIENTS AND METHODS Eight hundred twenty-nine metastatic… CONTINUE READING
Highly Influential
This paper has highly influenced 62 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS